Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases

Wanruchada Katchamart1*, Pintip Ngamjanyaporn2, Annop Orawongpaisarn1, Thossapoom Phubangkertphon3, Sasimon Borrirukwisitsak3 and Nichapa Dechapaphapitak2

Abstract
Background: Rituximab (RTX), anti-CD 20 monoclonal antibodies, has been approved for many rheumatic and autoimmune diseases, the use of RTX is still limited due to financial constrain. Biosimilar RTX may increase access by offering patients a more affordable option, lead to improved patient outcomes. However, real-world data related to its immediate and short-term safety is scarce. This study aimed to evaluate the real-world immediate and short-term safety profiles of CT-P10, a biosimilar of Rituximab, in patients with rheumatic and autoimmune diseases.

Methods: This prospective study included patients diagnosed with rheumatic or autoimmune diseases, aged ≥ 18 years, who were treated with biosimilar RTX at Siriraj or Ramathibodi Hospital during February 2019 to May 2019. Patients were followed up through 6 months after the infusions.

Results: Of the 74 patients, with 124 infusions, 84% were females with mean age (SD) of 49.4 (15.7) years. The most common rheumatic and autoimmune disease included in this study was systemic lupus erythematosus (26%). All immediate adverse events (AEs) (15 out of 124 infusions) were mild requiring only symptomatic and supportive treatment. Short-term AEs included infection (N = 35), hematologic abnormalities (N = 33), chylous ascites (N = 1), and others (N = 10). Two deaths were related to serious bacterial and viral infection. Hematologic AEs comprised anemia (N = 5), neutropenia (N = 10), lymphopenia (N = 15), and thrombocytopenia (N = 3).

Conclusion: In this real-world study, biosimilar RTX (CT-P10) has favorable immediate and short-term safety profiles. However, further studies with large sample size and long-term follow-up in real-world practice are still required to confirm the result.

Keywords: Rituximab, CT-P10, Biosimilar anti-CD 20 antibodies, Adverse event, Infusion reaction

Introduction

Rituximab (RTX), anti-CD 20 monoclonal antibodies, is a widely used biologic agent for treatment of rheumatic and autoimmune diseases [1], including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), idiopathic inflammatory myopathy (IIM), and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Furthermore, other indications for rituximab in non-rheumatic and autoimmune diseases are chronic lymphocytic leukemia and non-Hodgkin lymphoma [1]. A systemic review [2] demonstrated its efficacy and safety profiles of RTX in combination with methotrexate over placebo plus methotrexate for the treatment of refractory RA, while its
adverse events are comparable to those in placebo group. Its adverse events comprise infusion reactions, infections [3], and hematologic abnormalities, such as neutropenia [4]. Most adverse events are mild to moderate and associated with first infusion. Although RTX has been approved for many rheumatic and autoimmune diseases, the use of RTX is still limited. Many factors constraining patient access to RTX for the treatment of rheumatic and autoimmune diseases included restrictive treatment guidelines, administrative hurdles, and financial constraint. The availability of biosimilars may reduce barriers to access by offering patients a more affordable option, lead to improved patient outcomes.

CT-P10 (Truxima®) is a biosimilar of RTX approved by European Medicines Agency and Thai Food and Drug Administration for follicular lymphoma, diffuse large B cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, RA, granulomatosis with polyangiitis, and pemphigus vulgaris. Based on the totality of evidence, both in vitro studies and clinical trials suggested that CT-P10 is highly similar to its reference product in terms of chemical structure, purity, biological activity, safety, efficacy, and immunogenicity in patients with RA. Nonetheless, real-world data related to its safety is scarce. The aim of this study was to evaluate the real-world immediate and short-term safety profiles of CT-P10 in patients with rheumatic and autoimmune diseases.

**Methods**

This prospective study included patients who were diagnosed with rheumatic or autoimmune diseases at age of 18 years or older and received CT-P10 at Siriraj hospital and Ramathibodi hospital, Mahidol University, Bangkok, Thailand between February 2019 and May 2019. Written informed consent was obtained from all participants prior to enrollment.

Demographic data, baseline characteristics, and clinical data related to CT-P10 infusion were collected at baseline and 6 months after infusions for occurrences of adverse reactions. Adverse events (AEs) were stratified into immediate and short-term AE. Immediate AE was defined as any reactions that occurred within 24 h after infusion, include infusion reactions and anaphylaxis. Short-term AE was defined as any adverse events that occurred at 24 h until 6 months after infusion, including hematologic abnormality, elevated liver enzyme, infections, as well as other AEs. Severity of AEs was graded based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 5 [5] (Additional file 1: Table S1). The causal relationship of AE was adjusted and documented based on the WHO-UMC Causality Categories [6] (Additional file 1: Table S2).

This study was approved by the Siriraj Institutional Review Boards (COA no. Si 671/2018) and Ramathibodi Institutional Review Boards (COA no. MURA2019/124). All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants prior to enrolling in the study.

All statistical analyses were performed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, N.Y., USA). For the quantitative data, descriptive statistics are expressed as mean ± standard deviation (SD) for normal distributed data, or median (IQR) values for non-normal distributed data. For the qualitative data, number and percentage (%) are reported. To compare patients with and without infection-related AE, continuous data were analysed using the independent t-test or the Mann–Whitney U-test, while proportions were analysed using X² test or Fisher-exact tests, as appropriate.

**Results**

A total of 74 patients, receiving 124 infusions were included in this analysis. Of these, 83.8% were females with mean age (SD) of 49.4 (15.7) years. The most common rheumatic and autoimmune disease was SLE (25.7%), followed by RA (24.3%), adult-onset immunodeficiency with anti-interferon gamma autoantibody (12.2%), and pemphigus vulgaris (10.8%). Prednisolone was the most common concomitant medication (68.9%), followed by antimalarials (41.9%), and methotrexate (27%) (Table 1). Indication for RTX were inadequate response to standard treatment (92%), experienced adverse events related to standard treatment (30%), and physicians’ discretion based on disease severity (2.7%). One-third (37.8%) were previously treated with RTX prior to enrollment, 21.6% RTX-biosimilar and 16.2% RTX-originator. The main reason for switching from originator to biosimilar was financial problem (98%).

**Immediate adverse events**

There was 15 immediate AEs, including 6 infusion reactions, 5 skin reactions, and 4 respiratory symptoms (Table 2). All immediate AEs were mild requiring only symptomatic and supportive treatment, including temporary infusion interruption, and treatment with antihistamine and short-course glucocorticoid. Neither severe infusion reaction nor anaphylaxis was found in this study.
Regarding short-term AEs (Table 3), there were 35 events related to infection, 33 hematologic abnormalities, 10 other AEs, and 2 deaths. Causes of death of all patients were related to severe infection.

For infection, viral infection was the most common AE, 10 episodes of upper respiratory tract infection, 2 episodes of cytomegalovirus (CMV) viremia, 1 episode of gastroenteritis, 1 episode of varicella infection, and 1 episode of herpes infection. Most viral infections (87%) were mild to moderate, except a 49-year-old woman who was diagnosed of systemic sclerosis with nonspecific interstitial pneumonitis, active myopathy, and neuropathy developed CMV pneumonia and finally died of respiratory failure 20 days after the first dose of 1000 mg of CT-P10 infusion. Bacterial infections occurred 14 episodes (4 episodes of diarrhea and pseudomonas septicemia each, 3 episodes of E. coli septicemia, 2 episodes of acute cholangitis, 1 episode of gram-negative septicemia). One patient with pemphigus vulgaris died of severe pneumonia caused by Pseudomonas aeruginosa, and Enterococcus spp., which was 10 days after the first dose of 500 mg of CT-P 10 infusion. For fungal infections, there were 3 episodes of pneumocystis pneumonia, 2 episodes of invasive pulmonary aspergillosis (IPA), and 1 episode of cutaneous candidiasis. One patient with IPA developed ruptured aneurysm at left upper lung. Two episodes of mycobacterial infection were caused by mycobacterium avium complex and non-tuberculous mycobacterium spp.

For hematologic abnormalities, anemia, neutropenia, lymphopenia, and thrombocytopenia were found in 5, 10, 15, and 3 episodes, respectively. However, all of them were asymptomatic.

Other uncommon short-term AEs comprised elevated liver enzymes (n=6), chylous ascites (n=1), myalgia (n=1), fatigue (n=1), and nausea/vomiting (n=1). All these AEs were mild to moderate requiring no treatment.

There was no difference between age, sex, underlying rheumatic or autoimmune diseases, steroid use, immunosuppressive agent or disease modifying antirheumatic.

---

**Table 1** Baseline characteristics of study population (N=74 cases)

| Baseline characteristics | N (%) or mean ± SD |
|--------------------------|--------------------|
| Age                      | 49.38 ± 15.70      |
| Female                   | 62 (83.8)          |
| Underlying disease       |                    |
| Rheumatoid arthritis     | 16 (21.6)          |
| Systemic lupus erythematosus | 18 (24.3)      |
| Adult-onset immunodeficiency with anti-IFN-gamma autoantibody | 9 (12.2) |
| Pemphigus vulgaris       | 8 (10.8)           |
| Sjogren’s syndrome       | 5 (6.8)            |
| Inflammatory myopathy    | 5 (6.8)            |
| IgG4-related disease     | 2 (2.7)            |
| Focal segmental glomerulosclerosis | 1 (1.4) |
| Systemic sclerosis       | 2 (2.7)            |
| Neuromyelitis optica     | 1 (1.4)            |
| Granulomatosis with polyangiitis | 5 (6.8) |
| Overlapping syndrome     | 2 (2.7)            |
| RA + SLE                 | 1 (1.4)            |
| RA + Sjogren’s syndrome  | 1 (1.4)            |
| Concomitant medications  |                    |
| Prednisolone             | 51 (68.9)          |
| Antimalarial agent       | 31 (41.9)          |
| Methotrexate             | 20 (27.0)          |
| Azathioprine             | 16 (21.6)          |
| Cyclophosphamide         | 16 (21.6)          |
| Cyclosporine             | 8 (10.8)           |
| Mycophenolate mofetil    | 10 (13.5)          |
| Leflunomide              | 10 (13.5)          |
| Sulfasalazine            | 5 (6.8)            |
| Chlorambucil             | 2 (2.7)            |
| Dexamethasone            | 2 (2.7)            |
| Tacrolimus               | 1 (1.4)            |
| Intravenous immunoglobulin | 1 (1.4)         |

IFN, interferon gamma; IgG, immunoglobulin; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus

---

**Table 2** Immediate adverse events in 124 infusions

| Adverse events (N = 15 events) | Number of events (%) |
|---------------------------------|----------------------|
| Infusion reaction                |                      |
| Grade 1                          | 4 (3.2)              |
| Grade 2                          | 2 (1.6)              |
| Grade 3                          | 0 (0.0)              |
| Grade 4                          | 0 (0.0)              |
| Grade 5                          | 0 (0.0)              |
| Skin                             |                      |
| Rash                             | 0 (0.0)              |
| Flushing                         | 4 (3.2)              |
| Itching                          | 1 (0.8)              |
| Mucosa (angioedema)              | 0 (0.0)              |
| Respiratory                      |                      |
| Shortness of breath              | 4 (3.2)              |
| Wheeze                           | 0 (0.0)              |
| Stridor                          | 0 (0.0)              |
| Cough                            | 0 (0.0)              |
| Hypoxemia                        | 0 (0.0)              |
Discussion

While a systematic review and meta-analysis [2] reported that 29–38% of patients with RA developed immediate AEs during the 1st infusion of RTX originator, we found only 15 immediate AEs out of 124 infusions (12%) from RTX biosimilar in this study. Although the discrepancy may be caused by a small sample size in this study, this available data suggested that the immediate AEs related to CT-P10 infusion was acceptable.

From recent systematic review and meta-analysis [7] in which aimed to assess the difference in rate of infections between biologic RTX and non-RTX treatment in patients with RA, there was no significant difference between biologic RTX and non-RTX groups in overall infections rate (43.3% vs 44.9%; odds ratio [OR] = 0.87; 95% CI 0.70–1.08). Subgroup analysis also showed no significant differences in overall infections rate between biologic RTX versus placebo or other immunosuppressive agents, so an incidence of infections from RTX was suspected to be confounded by these concomitant medications.

Similar to previous report of RTX originator in real-world databases, hematologic abnormalities was the most common AE, mostly were lymphopenia, followed...
by neutropenia [8, 9]. For lymphopenia, this also directly related to the mechanism of action of anti-CD20 monoclonal antibodies, which is B-cell depletion leading to attenuating immune dysregulation in rheumatic and autoimmune diseases. Patients with lymphopenia are susceptible to viral infections, such as cytomegalovirus, herpes, and varicella as shown in our study.

For neutropenia, the recent French registry, called “AutoImmunity and Rituximab (AIR) registry” [8], reported the prevalence of neutropenia in RA and autoimmune diseases were 1.3% and 2.3%, respectively. Median time after infusion to onset of neutropenia was 102 (40–362) days [9], resulted in 7 hospitalizations. In our study, prevalence of neutropenia in RA and autoimmune diseases was similar to previous study (less than 5%). Only 1 of 9 patients with bacterial, fungal, or mycobacterial infection had neutropenia.

Regarding elevated liver enzymes, chylous ascites, and constitutional symptoms, we still had limited information related to these adverse events. Elevation of liver enzymes related to RTX infusions was reported in previous study [10] in patients with chronic lymphocytic leukemia who received RTX originator leading to a recommendation of closely monitoring liver enzymes after RTX treatment. From recent case-report [11] of patient with overlap syndrome of mixed connective tissue disease and SLE with chylous ascites, there was an excellent resolution of chylous ascites after biologic RTX infusion, so we suspected that the chylous ascites may be incidentally found in our study and not be associated with biosimilar RTX. We still need more information to interpret these findings.

Some limitations need to be concerned in this study. First, the number of patients included in this study was quite low, consequently uncommon or rare adverse events may not be discovered. Second, the diversity of underlying rheumatic or autoimmune diseases in this study may lead to various incidence of adverse events due to disease itself or concomitant medications for those conditions. Lastly, there was no control group with RTX originator in this study. Therefore, the AE-related to RTX biosimilar relative to RTX originator is still unclear and merits exploration.

Despite all these limitations, our study showed that CT-P10, biosimilar RTX, has favorable immediate and short-term safety profiles in real-world. However, further pharmacovigilance studies with large sample size and long-term follow up are still required to confirm its safety.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s41927-022-00306-7.

Additional file 1: Table S1. Definitions of severity (based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 5). Table S2. WHO-UMC causality categories. Table S3. Factors associated with bacterial infection (N = 74). Table S4. Factors associated with viral infection (N = 74). Table S5. Factors associated with fungal infection (N = 74).

Acknowledgements

We thanks Khemajira Karaketklang of the Research & Academic Services Unit, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University for assistance with statistical analysis and Dr. Pongthorn Narongroeknawin for his advice in study design.

Author contributions

WK and PN made substantial contributions to the conception, design of the work, the acquisition, analysis, interpretation of data, drafted the work or substantially revised it and approved the submitted version. AO, TP, SI, and ND made substantial contributions to the acquisition, analysis, interpretation of data, drafted the work or substantially revised it and approved the submitted version. All authors read and approved the final manuscript.

Funding

The investigational drug, CT-P10 (Truxima®), were funded by Celltrion, Ltd. Sponsor had no role in the design of the study, the data collection, as well as analysis and interpretation of the data. The decision to submit and publish this manuscript was contingent only on the approval of the lead author and co-authors.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Siriraj Institutional Review Boards (COA no. Si 671/2018, Oct 18, 2018) and Ramathibodi Institutional Review Boards (COA no. MURA2019/124, Jan 29, 2019). Informed consent was obtained from all subjects involved in the study prior to enrollment.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflicts of interest.

Author details

1. Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand. 2. Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 3. Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Received: 1 April 2022 Accepted: 26 September 2022

Published online: 30 November 2022

References

1. Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: Serious adverse events associated with the use of rituximab—a critical care perspective. Crit Care (Lond, Engl). 2012;16(4):231.
2. Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31(1):1493–9.
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–400.
4. Weissmann-Brenner A, Brenner B, Belyaeva I, Lahav M, Rabizadeh E. Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis. Med Sci Monit Int Med J Exp Clin Res. 2011;17(11):CS133–7.
5. U.S. Department of Health and Human Service. Common Terminology Criteria for Adverse Events (CTCAE). 2017. [cited 2020 April 1]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
6. The use of the WHO-UMC system for standardised case causality assessment. [cited 2020 April 12]. https://www.who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.
7. Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22(8):1361–70.
8. Salmon JH, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1(1):e000034.
9. Tesfa D, Ajjeganaova S, Hägglund H, Sander B, Fadeel B, Hafström I, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63(8):2209–14.
10. Toprak SK, Karakuş S. Rituximab-related reversible hepatocellular damage. Turk J Haematol Off J Turk Soc Haematol. 2012;29(4):422–4.
11. Daniel A, Bagnato G, Vital E, Del Galdo F. Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab. BMJ Case Rep. 2017;2017:bcr-2017.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.